Prospects for the treatment of systemic autoimmune rheumatic diseases. What intensive care physicians need to know

In the spectrum of rheumatic diseases, systemic autoimmune rheumatic diseases (SARDs) are of particular interest. Despite the dramatic improvement in the prognosis for SARD, associated with the improvement of the treatment strategy (treat-to-target) and the introduction of new effective anti-inflammatory drugs, more than 10% of patients with SARD develop severe organ pathology, potentially requiring treatment in intensive care units (ICUs). This article presents an analysis of the clinical and pathological manifestations that define the “severe” course of SARS. The prospects for pharmacotherapy for patients with SARS in the ICU setting are also discussed. The article opens a series of planned publications in the journal concerning the diagnosis and treatment of severe complications of SARDs.

1. van der Heijde D, Daikh DI, Betteridge N, Burmester GR, Hassett AL, Matteson EL, et al. Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Ann Rheum Dis. 2018;77(6):829-832. doi: 10.1136/annrheumdis-2017-212565

2. Nasonov EL. Modern concept of autoimmunity in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(4):397-420 (In Russ.). doi: 10.47360/1995-4484-2023-397-420

3. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: A comprehensive update. J Intern Med. 2015;278(4):369-395. doi: 10.1111/joim.12395

4. Szekanecz Z, McInnes IB, Schett G, Szamosi S, Benkő S, Szűcs G. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-595. doi: 10.1038/s41584-021-00652-9

5. Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: An urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 2023;80:102266. doi: 10.1016/j.coi.2022.102266

6. Abend AH, He I, Bahroos N, Christianakis S, Crew AB, Wise LM, et al. Estimation of prevalence of autoimmune diseases in the United States using electronic health record data. J Clin Invest. 2024;135(4):e178722. doi: 10.1172/JCI178722

7. Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: A population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401(10391):1878-1890. doi: 10.1016/S0140-6736(23)00457-9

8. Li M, Wu C, Yin P, Qian J, Zhao J, Wang Q, et al. Mortalityrelated health metrics in systemic autoimmune diseases: An epidemiological analysis of a nationwide register-based cohort. Sci Bull (Beijing). 2025;70(4):492-495. doi: 10.1016/j.scib.2024.12.021

9. Nasonov EL. Advances in pharmacotherapy for immunoinflammatory rheumatic diseases in the 21st century. Terapevticheskii arkhiv. 2025;97(5):401-411 (In Russ.). doi: 10.26442/00403660.2025.05.203213

10. Marinho A, Delgado Alves J, Fortuna J, Faria R, Almeida I, Alves G, et al. Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren’s syndrome: Evidenceand practice-based guidance. Front Immunol. 2023;14:1117699. doi: 10.3389/fimmu.2023.1117699

11. Schmid AS, Neri D. Advances in antibody engineering for rheumatic diseases. Nat Rev Rheumatol. 2019;15(4):197-207. doi: 10.1038/s41584-019-0188-8

12. Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, Gadina M, Heinz LX, et al. Selectivity, efficacy and safety of JAKinibs: New evidence for a still evolving story. Ann Rheum Dis. 2024;83(2):139-160. doi: 10.1136/ard-2023-223850

13. Nasonov EL, Korotaeva TV. Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(2):131-148 (In Russ.). doi: 10.47360/1995-4484-2022-131-148

14. Quintero OL, Rojas-Villarraga A, Mantilla RD, Anaya JM. Autoimmune diseases in the intensive care unit. An update. Autoimmun Rev. 2013;12(3):380-395. doi: 10.1016/j.autrev.2012.06.002

15. Dumas G, Arabi YM, Bartz R, Ranzani O, Scheibe F, Darmon M, et al. Diagnosis and management of autoimmune diseases in the ICU. Intensive Care Med. 2024;50(1):17-35. doi: 10.1007/s00134-023-07266-7

16. Ramírez-Lara E, Mendoza-Pinto C, Munguía-Realpozo P, Saavedra-Salinas MÁ, Etchegaray-Morales I, Ayón-Aguilar J, et al. Systemic lupus erythematosus in critical care: A systematic review of ICU outcomes and management. Autoimmun Rev. 2025;24(12):103911. doi: 10.1016/j.autrev.2025.103911

17. Auyezkhankyzy D, Izekenova A, Kocyigit BF. Emergencies in inflammatory rheumatic diseases. Rheumatol Int. 2024;44(9):1637-1646. doi: 10.1007/s00296-024-05660-y

18. Nagy G, Gunkl-Tóth L, Dorgó AM, McInnes IB. The concept of difficult-to-treat disease in rheumatology: Where next? Lancet Rheumatol. 2025;7(4):e274-e289. doi: 10.1016/S26659913(24)00340-0

19. Roccatello D, Sciascia S, Rossi D, Fenoglio R. Refractory systemic lupus erythematosus: Identification and pharmacological management. Drugs. 2023;83(2):117-134. doi: 10.1007/s40265-02201824-x

20. Kandane-Rathnayake R, Louthrenoo W, Lau CS, Hamijoyo L, Cho J, Lateef A, et al. Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: Observations from a multinational Asia-Pacific cohort. Arthritis Res Ther. 2025;27(1):155. doi: 10.1186/s13075-025-03622-8

21. Parodis I, Wincup C, Touma Z, Andersen J, Strand V, Sjöwall C. Holistic approaches in systemic lupus erythematosus: Do physicians avoid addressing difficult-to-treat but highly relevant symptoms? RMD Open. 2025;11(1):e005400. doi: 10.1136/rmdopen-2024-005400

22. Szűcs G, Szekanecz Z, Szamosi S. Can we define difficult-to-treat systemic sclerosis? Expert Rev Clin Immunol. 2024;20(9):10651081. doi: 10.1080/1744666X.2024.2352450

23. Bertoglio IM, Valim JML, Daffre D, Aikawa NE, Silva CA, Bonfá E, et al. Poor prognosis of COVID-19 acute respiratory distress syndrome in lupus erythematosus: Nationwide cross-sectional population study of 252 119 patients. ACR Open Rheumatol. 2021;3(11):804-811. doi: 10.1002/acr2.11329

24. D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: A US multicenter, comparative cohort study. Arthritis Rheumatol. 2021;73(6):914-920. doi: 10.1002/art.41619

25. Patel NJ, Srivatsan S, Kowalski EN, King A, Wang X, Vanni KM, et al. Patients with systemic autoimmune rheumatic diseases remain at risk for hospitalisation for COVID-19 infection in the Omicron era (2022–2024): A retrospective cohort study. RMD Open. 2025;11(1):e005114. doi: 10.1136/rmdopen-2024-005114

26. Anzalone AJ, Jackson LE, Singh N, Danila MI, Reisher E, Patel RC, et al.; National COVID Cohort Collaborative Consortium. Long-term mortality following SARS-CoV-2 infection in rural versus urban dwellers with autoimmune or inflammatory rheumatic disease: A retrospective cohort analysis from the National COVID Cohort Collaborative. Arthritis Care Res (Hoboken). 2025;77(1):143-155. doi: 10.1002/acr.25421

27. Nasonov EL, Rumyantsev AG, Samsonov MYu. Pharmacotherapy of autoimmune rheumatic diseases – from monoclonal antibodies to CAR T cells: 20 years later. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2024;62(3):262-279 (In Russ.). doi: 10.47360/1995-4484-2024-262-279

28. Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402(10416):2034-2044. doi: 10.1016/S0140-6736(23)01126-1

29. Schett G, Müller F, Taubmann J, Mackensen A, Wang W, Furie RA, et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol. 2024;20(9):531-544. doi: 10.1038/s41584-024-01139-z

30. Dumas G, Géri G, Montlahuc C, Chemam S, Dangers L, Pichereau C, et al. Outcomes in critically ill patients with systemic rheumatic disease: A multicenter study. Chest. 2015;148(4):927935. doi: 10.1378/chest.14-3098

31. Larcher R, Pineton de Chambrun M, Garnier F, Rubenstein E, Carr J, Charbit J, et al. One-year outcome of critically ill patients with systemic rheumatic disease: A multicenter cohort study. Chest. 2020;158(3):1017-1026. doi: 10.1016/j.chest.2020.03.050

32. Chabert P, Danjou W, Mezidi M, Berthiller J, Bestion A, Fred AA, et al. Shortand long-term prognosis of acute critically ill patients with systemic rheumatic diseases: A retrospective multicentre study. Medicine (Baltimore). 2021;100(35):e26164. doi: 10.1097/MD.0000000000026164

33. Poli S, Sciorio F, Piacentini G, Pietrobelli A, Pecoraro L, Pieropan S. Acute respiratory failure in autoimmune rheumatic diseases: A review. J Clin Med. 2024;13(10):3008. doi: 10.3390/jcm13103008

34. Janssen NM, Karnad DR, Guntupalli KK. Rheumatologic diseases in the intensive care unit: Epidemiology, clinical approach, management, and outcome. Crit Care Clin. 2002;18(4):729-748. doi: 10.1016/s0749-0704(02)00025-8

35. Hassan R, Faruqui H, Alquraa R, Eissa A, Alshaiki F, Cheikh M. Classification criteria and clinical practice guidelines for rheumatic diseases. In: Almoallim H, Cheikh M (eds). Skills in rheumatology. Springer, Singapore;2021. doi: 10.1007/978-981-15-8323-0_25

36. Nasonov EL, Baranov AA, Godkov MA, Abaitova NE, Avdeeva AS, Beketova TV, et al. Interpretation of laboratory tests in immune-inflammatory rheumatic diseases. Moscow:GEOTAR-Media;2025 (In Russ.). doi: 10.33029/9704-8972-7-ILA-2025-1-176

37. Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39

38. Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: History and modernity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):397-412 (In Russ.). doi: 10.47360/19954484-2022-397-412

39. Fedorchenko Y, Auyezkhankyzy D, Permenov BA, Zimba O, Zaiats L. Intensive care unit admission and mortality in rheumatic diseases. Rheumatol Int. 2025;45(12):267. doi: 10.1007/s00296025-06028-6

40. Guo J, Huang Z, Huang M, He Y, Han B, Ma N, et al. Development of a novel simple model to predict mortality in patients with systemic lupus erythematosus admitted to the intensive care unit. Front Med (Lausanne). 2021;8:689871. doi: 10.3389/fmed.2021.689871

41. Bhargav A, Ramanathan V, Ramadoss R, Kavadichanda C, Mariaselvam CM, Negi VS, et al. Outcome of critically ill patients with systemic lupus erythematosus from a medical intensive care unit in Southern India. Lupus. 2023;32(12):1462-1470. doi: 10.1177/09612033231204074

42. Zamir G, Haviv-Yadid Y, Sharif K, Bragazzi NL, Watad A, Dagan A, et al. Mortality of patients with systemic lupus erythematosus admitted to the intensive care unit – A retrospective singlecenter study. Best Pract Res Clin Rheumatol. 2018;32(5):701-709. doi: 10.1016/j.berh.2019.01.013

43. Abdelwhab SM, Kotb LI, Sameer G, Dawa G. Predictors of admission to intensive care unit among systemic lupus erythematosus patients: Prospective study. Egypt Rheumatol Rehabil. 2022;49:1-11. doi: 10.1186/s43166-021-00102-0

44. Momtaz OM, Senara SH, Zaky SH. Mohammed ES. Critically ill systemic lupus erythematosus patients referred to the intensive care unit of Fayoum university hospital: Frequency, complications and outcome. Egypt Rheumatol. 2019;41:129-133. doi: 10.1016/j.ejr.2018.05.003

45. Tanimura S, Fujieda Y, Kono M, Shibata Y, Hisada R, Sugawara E, et al. Clinical significance of plasma presepsin levels in patients with systemic lupus erythematosus. Mod Rheumatol. 2018;28(5):865-871. doi: 10.1080/14397595.2017.1408755

46. Oud L. Epidemiology and outcomes of sepsis among hospitalizations with systemic lupus erythematosus admitted to the ICU: A population-based cohort study. J Intensive Care. 2020;8:3. doi: 10.1186/s40560-019-0424-y

47. Battaglia M, Garrett-Sinha LA. Bacterial infections in lupus: Roles in promoting immune activation and in pathogenesis of the disease. J Transl Autoimmun. 2020;4:100078. doi: 10.1016/j.jtauto.2020.100078

48. Dorgham DA, Anwar S, Shimaa-Khaled AI. Infection in systemic lupus erythematosus patients. Egypt Rheumatol. 2021;43:115-118. doi: 10.1016/j.ejr.2020.12.007

49. Chen Y, Shen J, Yang H, Xu S, Ma Y, Pan F. Serum procalcitonin and C-reactive protein levels as diagnostic markers for distinguishing bacterial infections from lupus flares in systemic lupus erythematosus: A systematic review and meta-analysis. Int Immunopharmacol. 2021;101(Pt B):108304. doi: 10.1016/j.intimp.2021.108304

50. Amarnani A, Liu F, Wilson ML, Lim N, Stohl W, Wise L. Discriminating disease flare from infection in febrile patients with systemic lupus erythematosus in a safety-net hospital system: A multicenter study. ACR Open Rheumatol. 2025;7(6):e70051. doi: 10.1002/acr2.70051

51. Rao M, Mikdashi J. A framework to overcome challenges in the management of infections in patients with systemic lupus erythematosus. Open Access Rheumatol. 2023;15:125-137. doi: 10.2147/OARRR.S295036

52. Hu BQ, Yang Y, Zhao CJ, Liu DF, Kuang F, Zhang LJ, et al. Accuracy of neutrophil CD64 expression in diagnosing infection in patients with autoimmune diseases: A meta-analysis. Clin Rheumatol. 2019;38(5):1319-1328. doi: 10.1007/s10067-019-04518-0

53. Ospina FE, Echeverri A, Zambrano D, Suso JP, Martínez-Blanco J, Cañas CA, et al. Distinguishing infections vs flares in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2017;56(Suppl 1):i46-i54. doi: 10.1093/rheumatology/kew340

54. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: A systematic review and metaanalysis. Lancet Infect Dis. 2013;13(5):426-435. doi: 10.1016/s1473-3099(12)70323-7

55. Keskin A, Aci R. Procalcitonin to albumin ratio as a biomarker for predicting mortality in sepsis. J Coll Physicians Surg Pak. 2024;34(3):360-363. doi: 10.29271/jcpsp.2024.03.360

56. Abdel-Magied RA, Mokhtar NW, Abdullah NM, Abdel-Naiem AM. Infection versus disease activity in systemic lupus erythematosus patients with fever. BMC Rheumatol. 2024;8(1):34. doi: 10.1186/s41927-024-00395-6

57. Ajmani S, Singh H, Chaturvedi S, Mishra R, Rai MK, Jain A, et al. Utility of neutrophil CD64 and serum TREM-1 in distinguishing bacterial infection from disease flare in SLE and ANCAassociated vasculitis. Clin Rheumatol. 2019;38(4):997-1005. doi: 10.1007/s10067-018-4334-5

58. Tejera Segura B, Rua-Figueroa I, Pego-Reigosa JM, Del Campo V, Wincup C, Isenberg D, et al. Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. BMJ Open. 2019;9(6):e028697. doi: 10.1136/bmjopen-2018-028697

59. Ramirez GA, Calabrese C, Secci M, Moroni L, Gallina GD, Benanti G, et al. Infection-associated flares in systemic lupus erythematosus. Pathogens. 2024;13(11):934. doi: 10.3390/pathogens13110934

60. Zhang B, Zheng L, Huang Y. Severe pneumonia in patients with systemic lupus erythematosus admitted to the intensive care unit. Z Rheumatol. 2024;83(Suppl 1):148-153. English. doi: 10.1007/s00393-022-01172-x

61. Schneeweiss-Gleixner M, Hillebrand C, Jaksits S, Fries J, Zauner M, Heinz G, et al. Characteristics and outcome of critically ill patients with systemic rheumatic diseases referred to the intensive care unit. RMD Open. 2023;9(4):e003287. doi: 10.1136/rmdopen-2023-003287

62. Quintana JH, Aragón CC, Santos VA, de Las Salas A, Tafúr RA, Aguirre-Valencia D, et al. Diffuse alveolar hemorrhage: A cohort of patients with systemic lupus erythematosus. J Clin Rheumatol. 2020;26(7S Suppl 2):S153-S157. doi: 10.1097/RHU.0000000000001228

63. Kraeva VV, Beketova TV. Pulmonary hemorrhage in rheumatic diseases. Terapevticheskii arkhiv. 2019;91(5):76-83 (In Russ.). doi: 10.26442/00403660.2019.05.000234

64. Mudgal M, Balaji S, Gajendiran AP, Subramanya A, Murugan SK, Gondhi V, et al. Connective tissue disorder-induced diffuse alveolar hemorrhage: A comprehensive review with an emphasis on airway and respiratory management. Life (Basel). 2025;15(5):793. doi: 10.3390/life15050793

65. Garcia-Villanueva MJ, Garrote-Corral S, Pego-Reigosa JM, Jiménez Otero N, Uriarte Isazelaia E, Olivé Marqué A, et al. Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: Data from the Spanish society of rheumathology Lupus Register (RELESSER). Rheumatol Int. 2024;44(11):2445-2455. doi: 10.1007/s00296-024-05684-4

66. Jiang M, Chen R, Zhao L, Zhang X. Risk factors for mortality of diffuse alveolar hemorrhage in systemic lupus erythematosus: A systematic review and meta-analysis. Arthritis Res Ther. 2021;23(1):57. doi: 10.1186/s13075-021-02435-9

67. Li M, Bai W, Wang Y, Song L, Zhang S, Zhao J, et al. Infection in systemic lupus erythematosus-associated diffuse alveolar hemorrhage: A potential key to improve outcomes. Clin Rheumatol. 2023;42(6):1573-1584. doi: 10.1007/s10067-023-06517-8

68. Motairek I, Abdulhai F, Badwan O, Issa R, Calcagno T, Mirzai S, et al. Sex differences in cardiovascular mortality among patients with immune mediated inflammatory diseases. Circ Cardiovasc Qual Outcomes. 2025;18(5):e011833. doi: 10.1161/CIRCOUTCOMES.124.011833

69. Lu X, Wang Y, Zhang J, Pu D, Hu N, Luo J, et al. Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and meta-analysis. Int Immunopharmacol. 2021;94:107466. doi: 10.1016/j.intimp.2021.107466

70. Bello N, Meyers KJ, Workman J, Hartley L, McMahon M. Cardiovascular events and risk in patients with systemic lupus erythematosus: Systematic literature review and meta-analysis. Lupus. 2023;32(3):325-341. doi: 10.1177/09612033221147471

71. Yazdany J, Pooley N, Langham J, Nicholson L, Langham S, Embleton N, et al. Systemic lupus erythematosus; stroke and myocardial infarction risk: A systematic review and meta-analysis. RMD Open. 2020;6(2):e001247. doi: 10.1136/rmdopen-2020-001247

72. Zen M, Salmaso L, Barbiellini Amidei C, Fedeli U, Bellio S, Iaccarino L, et al. Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large populationbased study. Eur J Intern Med. 2023;112:45-51. doi: 10.1016/j.ejim.2023.02.004

73. Çetin Ç, Can MG, Öztaşkın S, Yalçınkaya Y, Gül A, İnanç M, et al. Analysis of 5-year hospitalization data of patients with systemic lupus erythematosus: Damage is a risk factor for frequent and longer stays. Lupus. 2024;33(3):232-240. doi: 10.1177/09612033241227023

74. Ding T, Fan Y, Zhang X, Zhang Z. Refractory lupus nephritis: Current understanding and emerging treatment strategies. Clin Exp Med. 2025;26(1):78. doi: 10.1007/s10238-025-02014-1

75. Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: Clinical presentations and outcomes in the 21st century. Rheumatology (Oxford). 2020;59(Suppl 5):v39-v51. doi: 10.1093/rheumatology/keaa381

76. Lertwises S, Rattanasupar A, Chang A. Factors predictive of inhospital mortality in patients with systemic lupus erythematosus: A single-centre retrospective analysis. Acta Med Acad. 2023;52(1):37-46. doi: 10.5644/ama2006-124.400

77. Mahajan A, Amelio J, Gairy K, Kaur G, Levy RA, Roth D, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: A pragmatic review mapping disease severity and progression. Lupus. 2020;29(9):1011-1020. doi: 10.1177/0961203320932219

78. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: Challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133(9):906-918. doi: 10.1182/blood-2018-11-882993

79. Kaiser R, Gold C, Stark K. Recent advances in immunothrombosis and thromboinflammation. Thromb Haemost. 2025;125(12):1181-1194.

80. Nasonov EL, Reshetnyak TM, Alekberova ZS. Thrombotic microangiopathy in rheumatology: A link between thrombosis and autoimmunity. Terapevticheskii arkhiv. 2020;92(5):4-14. (In Russ.). doi: 10.26442/00403660.2020.05.000697

81. Leisring J, Brodsky SV, Parikh SV. Clinical evaluation and management of thrombotic microangiopathy. Arthritis Rheumatol. 2024;76(2):153-165. doi: 10.1002/art.42681

82. Genest DS, Patriquin CJ, Licht C, John R, Reich HN. Renal thrombotic microangiopathy: A review. Am J Kidney Dis. 2023;81(5):591-605. doi: 10.1053/j.ajkd.2022.10.014

83. Kotzen ES, Roy S, Jain K. Antiphospholipid syndrome nephropathy and other thrombotic microangiopathies among patients with systemic lupus erythematosus. Adv Chronic Kidney Dis. 2019;26(5):376-386. doi: 10.1053/j.ackd.2019.08.012

84. Xie Xiaodong MM, Wang Guoqin MD, Cheng Hong MD, Sun Lijun MM, Dong Hongrui BM. Scleroderma-associated thrombotic microangiopathy in overlap syndrome of systemic sclerosis and systemic lupus erythematosus: A case report and literature review. Medicine. 2020;99(41):e22582. doi: 10.1097/MD.0000000000022582

85. Li J, Jiang JJ, Wang CY, Jian S, Zhou Y, Ma MS, et al. Clinical features and prognosis of patients with thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: A review of 25 cases. Ital J Pediatr. 2019;45(1):55. doi: 10.1186/s13052-019-0641-y

86. Couture P, Hie M, Pineton de Chambrun M, Galicier L, Costedoat-Chalumeau N, Deroux A, et al. Systemic lupus erythematosus-associated thrombotic microangiopathies in 60 patients: Clinical features, prognosis and treatment in a French multicentric cohort. Ann Rheum Dis. 2018;77:688-689. doi: 10.1136/annrheumdis-2018-eular.687

87. Gai Y, Li M, Zhu Z, Zhou Y, Huang C, Bai W, et al. Systematic review of the outcomes and prognostic factors of patients with systemic lupus erythematosus-associated thrombotic microangiopathy. Kidney Int Rep. 2025;10(7):2243-2254. doi: 10.1016/j.ekir.2025.04.022

88. Fayed A, Elgohary R, Shaker AM, Salem KM, Desouky EE, Maghraby GG. Outcome of proliferative lupus nephritis with thrombotic microangiopathy; An ambispective observational single-center study. BMC Nephrol. 2025;26(1):233. doi: 10.1186/s12882-025-04154-8

89. Martis N, Jamme M, Bagnis-Isnard C, Pouteil-Noble C, Presne C, Vigneau C, et al.; French Reference Centre for Thrombotic Microangiopathies. Systemic autoimmune disorders associated with thrombotic microangiopathy: A cross-sectional analysis from the French National TMA registry: Systemic autoimmune disease-associated TMA. Eur J Intern Med. 2021;93:78-86. doi: 10.1016/j.ejim.2021.05.040

90. Chen Z, Zhong H, Dong G. Thrombocytopenia as a prognostic marker for systemic lupus erythematosus: A systematic review and meta-analysis. Am J Med Sci. 2019;357(6):461-467. doi: 10.1016/j.amjms.2019.03.002

91. Nasonov EL (ed.). Antiphospholipid syndrome. Moscow:Litterra;2004 (In Russ.).

92. Reshetnyak TM. Classification criteria of antiphospholipid syndrome ACR/EULAR 2023 and comments on them. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2025;63(1):12-23 (In Russ.). doi: 10.47360/1995-4484-2025-12-23

93. Jacobs L, Wauters N, Lablad Y, Morelle J, Taghavi M. Diagnosis and management of catastrophic antiphospholipid syndrome and the potential impact of the 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Antibodies (Basel). 2024;13(1):21. doi: 10.3390/antib13010021

94. Newman TG, Knight JS. Antiphospholipid syndrome: An antibody-mediated disease with emerging therapeutic opportunities. Arthritis Rheumatol. 2025;77(12):1626-1634. doi: 10.1002/art.43258

95. Salter BM, Crowther MA. Catastrophic antiphospholipid syndrome: A CAPS-tivating hematologic disease. Hematology Am Soc Hematol Educ Program. 2024;2024(1):214-221. doi: 10.1182/hematology.2024000544

96. Patriarcheas V, Tsamos G, Vasdeki D, Kotteas E, Kollias A, Nikas D, et al. Antiphospholipid syndrome: A comprehensive clinical review. J Clin Med. 2025;14(3):733. doi: 10.3390/jcm14030733

97. Bitsadze V, Yakubova F, Khizroeva J, Lazarchuk A, Salnikova P, Vorobev A, et al. Catastrophic antiphospholipid syndrome. Int J Mol Sci. 2024;25(1):668. doi: 10.3390/ijms25010668

98. Rodríguez-Pintó I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, et al.; CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies). Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016;15(12):1120-1124. doi: 10.1016/j.autrev.2016.09.010

99. Doyle TJ, Dellaripa PF. Lung manifestations in the rheumatic diseases. Chest. 2017;152(6):1283-1295. doi: 10.1016/j.chest.2017.05.015

100. Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. Lancet. 2021;398(10300):622-637. doi: 10.1016/s0140-6736(21)00439-6

101. Boyle N, O’Callaghan M, Ataya A, Gupta N, Keane MP, Murphy DJ, et al. Pulmonary renal syndrome: A clinical review. Breathe (Sheff). 2022;18(4):220208. doi: 10.1183/20734735.02082022

102. Ponticelli C, Calatroni M, Moroni G. Anti-glomerular basement membrane vasculitis. Autoimmun Rev. 2023;22(1):103212. doi: 10.1016/j.autrev.2022.10321

103. Nasonov EL, Ananyeva LP, Belevsky AS. Interstitial lung diseases and autoimmunity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2025;63(2):119-128 (In Russ.). doi: 10.47360/19954484-2025-119-128

104. Boyle N, Miller J, Quinn S, Maguire J, Fabre A, Morrisroe K, et al. Systemic autoimmune rheumatic diseases-associated interstitial lung disease: A pulmonologist’s perspective. Breathe (Sheff). 2025;21(2):240171. doi: 10.1183/20734735.0171-2024

105. Yuan W, Zhou X, Yang Y, Zhang S, He X, Ji J. Associated factors in the development of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis. Front Immunol. 2025;16:1628928. doi: 10.3389/fimmu.2025.1628928

106. Nasonov EL, Ananyeva LP, Avdeev SN. Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(6):517-534 (In Russ.). doi: 10.47360/1995-4484-2022-1

107. Joy GM, Arbiv OA, Wong CK, Lok SD, Adderley NA, Dobosz KM, et al. Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: A systematic review and meta-analysis. Eur Respir Rev. 2023;32(167):220210. doi: 10.1183/16000617.0210-2022

108. Ananyeva LP. Interstitial lung disease associated with systemic sclerosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(1):87-95 (In Russ.). doi: 10.14412/1995-4484-2017-87-95

109. Banuls L, Vanoverschelde J, Garnier F, Amalric M, Jaber S, Charbit J, et al. Interstitial lung disease worsens shortand longterm outcomes of systemic rheumatic disease patients admitted to the ICU: A multicenter study. J Clin Med. 2021;10(5):1037. doi: 10.3390/jcm10051037

110. Huapaya JA, Wilfong EM, Harden CT, Brower RG, Danoff SK. Risk factors for mortality and mortality rates in interstitial lung disease patients in the intensive care unit. Eur Respir Rev. 2018;27:180061. doi: 10.1183/16000617.0061-2018

111. Matson SM, Demoruelle MK. Connective tissue disease associated interstitial lung disease. Rheum Dis Clin North Am. 2024;50(3):423-438. doi: 10.1016/j.rdc.2024.03.001

112. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903-975. doi: 10.1183/13993003.01032-2015

113. Matusov G, Shams M, Ibrahim K, Hovsepyan A, Matusov Y. Risk factors for adverse outcomes in connective tissue diseaseassociated pulmonary hypertension. Rev Cardiovasc Med. 2025;26(3):26877. doi: 10.31083/RCM26877

114. Salvarani C, Hunder GG, Brown RD Jr. Primary central nervous system vasculitis. N Engl J Med. 2024;391(11):1028-1037. doi: 10.1056/NEJMra2314942

115. Legge AC, Hanly JG. Recent advances in the diagnosis and management of neuropsychiatric lupus. Nat Rev Rheumatol. 2024;20(11):712-728. doi: 10.1038/s41584-024-01163-z

116. Nigrovic PA. Macrophage activation syndrome. Arthritis Rheumatol. 2025;77(4):367-379. doi: 10.1002/art.43052

117. Wang J, Rong W, Yan H. Eighty-six cases of clinical characteristics and outcomes of systemic lupus erythematosus-associated macrophage activation syndrome: A meta-analysis study. Immun Inflamm Dis. 2024;12(8):e1364. doi: 10.1002/iid3.1364

118. Cohen EM, D’Silva K, Kreps D, Son MB, Costenbader KH. Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus. Lupus. 2018;27(7):1065-1071. doi: 10.1177/0961203318759428

119. Liu AC, Yang Y, Li MT, Jia Y, Chen S, Ye S, et al. Macrophage activation syndrome in systemic lupus erythematosus: A multicenter, case-control study in China. Clin Rheumatol. 2018;37(1):93-100. doi: 10.1007/s10067-017-3625-6

120. Abdirakhmanova A, Sazonov V, Mukusheva Z, Assylbekova M, Abdukhakimova D, Poddighe D. Macrophage activation syndrome in pediatric systemic lupus erythematosus: A systematic review of the diagnostic aspects. Front Med (Lausanne). 2024;8:681875. doi: 10.3389/fmed.2021.681875

121. Kim JM, Kwok SK, Ju JH, Kim HY, Park SH. Reactive hemophagocytic syndrome in adult Korean patients with systemic lupus erythematosus: A case-control study and literature review. J Rheumatol. 2012;39(1):86-93. doi: 10.3899/jrheum.110639

122. Wafa A, Hicham H, Naoufal R, Hajar K, Rachid R, Souad B, et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 20 Moroccan adult patients. Clin Rheumatol. 2022;41(7):2021-2033. doi: 10.1007/s10067-022-06055-9

123. Aziz A, Castaneda EE, Ahmad N, Veerapalli H, Rockferry AG, Lankala CR, et al. Exploring macrophage activation syndrome secondary to systemic lupus erythematosus in adults: A systematic review of the literature. Cureus. 2021;13(10):e18822. doi: 10.7759/cureus.18822

124. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. doi: 10.1016/S0140-6736(17)30933-9

125. Naranjo-Escobar J, Hormaza AA, Posso-Osorio I, Pino-Escobar J, Betancur JF, Tobón GJ. Systemic sclerosis at an intensive care unit: A case series and literature review. J Clin Rheumatol. 2019;25(4):181-185. doi: 10.1097/RHU.0000000000000827

126. Cole A, Ong VH, Denton CP. Renal disease and systemic sclerosis: An update on scleroderma renal crisis. Clin Rev Allergy Immunol. 2023;64(3):378-391. doi: 10.1007/s12016-02208945-x

127. Vigneron C, Pène F, Charpentier J, Mouthon L, Chaigne B. Scleroderma cardiac crisis: A-life-threatening but reversible complication of systemic sclerosis. Autoimmun Rev. 2022;21(10):103162. doi: 10.1016/j.autrev.2022.103162

128. Uribarri A, Guillen-Del Castillo A, Belahnech Y, Casas G, Gabaldón A, Bellera N, et al. Cardiogenic shock in systemic sclerosis: A retrospective study of acute ventricular dysfunction. Rheumatol Int. 2025;45(5):125. doi: 10.1007/s00296-025-05874-8

129. Cacoub P, Vieira M, Langford CA, Tazi Mezalek Z, Saadoun D. Large-vessel vasculitis. Lancet. 2025;406(10514):2017-2032. doi: 10.1016/S0140-6736(25)01436-9

130. von der Emde L, Petzinna SM, Herwig-Carl MC, Adamson MS, Bauer CJ, Esser J, et al. Advances in diagnosing and treating giant cell arteritis: New hope for arteritic anterior ischemic optic neuropathy. Surv Ophthalmol. 2026;71(2):483-497. doi: 10.1016/j.survophthal.2025.06.009

131. Raiker R, Pakhchanian H, DeYoung C, Gupta L, Kardeş S, Ahmed S, et al. Short term outcomes of COVID-19 in lupus: Propensity score matched analysis from a nationwide multi-centric research network. J Autoimmun. 2021;125:102730. doi: 10.1016/j.jaut.2021.102730

132. Bruera S, Lei X, Zhao H, Yazdany J, Chavez-MacGregor M, Giordano SH, et al. Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus. Lupus Sci Med. 2023;10(1):e000750. doi: 10.1136/lupus-2022-000750

133. Aseeva EA, Soloviev SK, Nasonov EL. New strategy for glucocorticoid use in systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2025;63(5):421-431 (In Russ.). doi: 10.47360/19954484-2025-421-431

134. Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762

135. Fanouriakis A, Kostopoulou M, Anders HJ, Andersen J, Aringer M, Beresford MW, et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis. 2026;85(1):75-90. doi: 10.1016/j.ard.2025.09.007

136. Beketova TV, Popov IYu, Babak VV. Review of guideline for the management of ANCAassociated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(6):684-692 (In Russ.). doi: 10.47360/1995-4484-2021-684-692

137. Sammaritano LR, Askanase A, Bermas BL, Dall’Era M, DuarteGarcía A, Hiraki LT, et al. 2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus. Arthritis Rheumatol. 2025 Nov 4. doi: 10.1002/art.43452

138. Sammaritano LR, Askanase A, Bermas BL, Dall’Era M, DuarteGarcía A, Hiraki LT, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol. 2025;77(9):11151135. doi: 10.1002/art.43212

139. Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, Čolić J, Santiago T, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025;84(1):29-40. doi: 10.1136/ard-2024-226430

140. Paik JJ, Werth VP, Chinoy H, Masri KR, Jambekar A, Hasan F, et al. Treatment guidelines for idiopathic inflammatory myopathies in adults: A comparative review. Rheumatology (Oxford). 2025;64(6):3288-3302. doi: 10.1093/rheumatology/keaf116

141. Biddle K, Jade J, Wilson-Morkeh H, Adikari M, Yaghchi CA, Anastasa Z, et al.; British Society for Rheumatology Guideline Steering Group. The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis. Rheumatology (Oxford). 2025;64(8):4470-4494. doi: 10.1093/ rheumatology/keaf240

142. Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int. 2024;105(3S):S71S116. doi: 10.1016/j.kint.2023.10.008

143. Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. doi: 10.1136/annrheumdis-2019-215213

144. Ambati A, Knight JS, Zuo Y. Antiphospholipid syndrome management: A 2023 update and practical algorithm-based approach. Curr Opin Rheumatol. 2023;35(3):149-160. doi: 10.1097/BOR.0000000000000932

145. Lincoln M, McGimsey T, O’Driscoll D. Rituximab in the intensive care unit: A review of indications and clinical considerations. J Intensive Care Med. 2025:8850666251409783. doi: 10.1177/08850666251409783

146. Yang Z, Liu S, Zong Z, Li Q, Yu L, Sun S. Treatment of thrombotic microangiopathy associated with systemic lupus erythematosus with low-dose rituximab as an induction agent and belimumab as a maintenance agent. BMC Pediatr. 2025;25(1):141. doi: 10.1186/s12887-025-05506-x

147. Nasonov EL, Reshetnyak TM, Beketova TV, Sukmarova ZN, Starkova AS. Intravenous immunoglobulin in rheumatology: New data and draft clinical guidelines. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2025;63(6):559-575 (In Russ.). doi: 10.47360/1995-4484-2025-559-575

148. Aguirre-Valencia D, Naranjo-Escobar J, Posso-Osorio I, MacíaMejía MC, Nieto-Aristizábal I, Barrera T, et al. Therapeutic plasma exchange as management of complicated systemic lupus erythematosus and other autoimmune diseases. Autoimmune Dis. 2019;2019:5350960. doi: 10.1155/2019/5350960

149. Bereanu AS, Pisaltu T, Bereanu R, Vintila B, Codru I, Chicea L, et al. Therapeutic plasma exchange in catastrophic antiphospholipid syndrome (CAPS): A rare case report and literature review. In Vivo. 2023;37(4):1914-1919. doi: 10.21873/invivo.13286

150. Rony RMIK, Shokrani A, Malhi NK, Hussey D, Mooney R, Chen ZB, et al. Therapeutic plasma exchange: current and emerging applications to mitigate cellular signaling in disease. Biomolecules. 2025;15(7):1000. doi: 10.3390/biom15071000

151. Rah W, Kwon OC, Ha JW, Park YB, Lee SW. Plasma exchange as an adjunctive therapeutic option for severe and refractory antineutrophil cytoplasmic antibody-negative microscopic polyangiitis and granulomatosis with polyangiitis. Medicina (Kaunas). 2025;61(12):2184. doi: 10.3390/medicina61122184

152. Bano S, Jawed I, Abdul Qadir MU, Abbas Rizvi SAF, Karmani VK, Alam F, et al. Evaluating the safety and efficacy of plasma therapy/plasmapheresis for systemic sclerosis – A comprehensive systematic review. Transfus Apher Sci. 2025;64(1):104036. doi: 10.1016/j.transci.2024.104036

153. Kim YK, Curtis JR, Choi SR, Yeo J, Kim MJ, Lee YJ, et al. Time-dependent effect of prophylactic trimethoprim-sulfamethoxazole on the incidence of serious infections in antineutrophil cytoplasmic antibody-associated vasculitis: A target trial emulation study. Arthritis Rheumatol. 2025;77(10):1407-1415. doi: 10.1002/art.43185

154. Györfi AH, Filla T, Polzin A, Tascilar K, Buch M, Tröbs M, et al.; EUSTAR collaborators. Evaluation of systemic sclerosis primary heart involvement and chronic heart failure in the European scleroderma trials and research cohort. J Am Heart Assoc. 2025;14(5):e036730. doi: 10.1161/JAHA.124.036730

155. Arnaud L, Ruiz-Irastorza G, Aranow C, Bernatsky S, Dall’Era M, Adelowo O, et al.; European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal, Diseases; Systemic Lupus Erythematosus International Collaborating Clinics group; European Lupus Society rare systemic lupus erythematosus taskforce member panel. ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. Lancet Rheumatol. 2025;7(7):e505-e518. doi: 10.1016/S2665-9913(25)00063-3

156. Danieli MG, Antonelli E, Gammeri L, Longhi E, Cozzi MF, Palmeri D, et al. Intravenous immunoglobulin as a therapy for autoimmune conditions. Autoimmun Rev. 2025;24(1):103710. doi: 10.1016/j.autrev.2024.103710

157. Nieto-Aristizábal I, Martínez T, Urbano MA, Posso-Osorio I, Plata IF, Garcia-Robledo JE, et al. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: A single-center experience with 63 patients. Lupus. 2019;28(13):1566-1570. doi: 10.1177/0961203319883680

158. Cajamarca-Barón J, Buitrago-Bohórquez J, Mendoza Orozco JE, Segura O, Guavita-Navarro D, Gallego-Cardona L, et al. Efficacy and safety of intravenous immunoglobulin in patients with lupus nephritis: A systematic review of the literature. Autoimmun Rev. 2022;21(11):103182. doi: 10.1016/j.autrev.2022.103182

159. Crickx E, Machelart I, Lazaro E, Kahn JE, Cohen-Aubart F, Martin T, et al.; French Vasculitis Study Group. Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: A French nationwide study of ninety-two patients. Arthritis Rheumatol. 2016;68(3):702-712. doi: 10.1002/art.39472

160. Benavides-Villanueva F, Loricera J, Calvo-Río V, Corrales-Selaya C, Castañeda S, Blanco R. Intravenous immunoglobulin therapy in antineutrophil cytoplasmic antibody-associated vasculitis. Eur J Intern Med. 2023;117:78-84. doi: 10.1016/j.ejim.2023.06.021

161. Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csörgő Z, Dimachkie MM, Griger Z, et al.; ProDERM Trial Group. Trial of intravenous immune globulin in dermatomyositis. N Engl J Med. 2022;387(14):1264-1278. doi: 10.1056/NEJMoa2117912

162. Koczanowski S, Morrisroe K, Fairley J, Nikpour M, Oon S, Brown Z. Role of intravenous immunoglobulins in systemic sclerosis (SSc): A systematic literature review. Semin Arthritis Rheum. 2024:152471. doi: 10.1016/j.semarthrit.2024.152471

163. Watson E, Minehan S, White R. It’s never Lupus … until it is; Primary neuropsychiatric systemic lupus erythematosus presenting as psychosis treated with intravenous immunoglobulin and rituximab: A case study. Neurology. 2017;88(S-16):6-191. doi: 10.1212/WNL.88.16_supplement.P6.191

164. Cheikh MM, Bahakim AK, Aljabri MK, Alharthi SM, Alharthi SM, Alsaeedi AK, et al. Neuropsychiatric lupus and lupus nephritis successfully treated with combined IVIG and rituximab: An alternative to standard of care. Case Rep Rheumatol. 2022;2022:5899188. doi: 10.1155/2022/5899188

165. Birnbaum J, Lalji A, Piccione EA, Izbudak I. Magnetic resonance imaging of the spinal cord in the evaluation of 3 patients with sensory neuronopathies: Diagnostic assessment, indications of treatment response, and impact of autoimmunity: A case report. Medicine (Baltimore). 2017;96(49):e8483. doi: 10.1097/MD.0000000000008483

166. Lima K, Tavee J, Dua A. Combination rituximab and intravenous immunoglobulin for treatment of refractory vasculitic neuropathy: A case series. Rheumatology (Oxford). 2021;60(10):4884-4887. doi: 10.1093/rheumatology/keab069

167. Hill JA, Giralt S, Torgerson TR, Lazarus HM. CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev. 2019;38:100596. doi: 10.1016/j.blre.2019.100596

168. Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA, et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the writing committee of the American Society for Apheresis: The ninth special issue. J Clin Apher. 2023;38(2):77-278. doi: 10.1002/jca.22043

169. Mina-Osorio P, Tran MH, Habib AA. Therapeutic plasma exchange versus FcRn inhibition in autoimmune disease. Transfus Med Rev. 2024;38(1):150767. doi: 10.1016/j.tmrv.2023.150767

170. Rockx MA, Clark WF. Plasma exchange for treating cryoglobulinemia: A descriptive analysis. Transfus Apher Sci. 2010;42(3):247-251. doi: 10.1016/j.transci.2010.03.001

171. Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: Advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179-199. doi: 10.1038/s41573-02000092-2

172. Mougiakakos D, Meyer EH, Schett G. CAR T cells in autoimmunity: Game changer or stepping stone? Blood. 2025;145(17):1841-1849. doi: 10.1182/blood.2024025413

173. Junt T, Calzascia T, Traggiai E, da Costa AN, Gergely P, Schett G, et al. Defining immune reset: Achieving sustained remission in autoimmune diseases. Nat Rev Immunol. 2025;25(7):528-541. doi: 10.1038/s41577-025-01141-w

174. Volkmann ER, Goklemez S, Varga J, Blazar BR, Pavletic SZ. Cellular therapy for systemic autoimmune diseases: New opportunities for future research and interdisciplinary collaboration. ACR Open Rheumatol. 2025;7(11):e70130. doi: 10.1002/acr2.70130

175. Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501-521. doi: 10.1038/s41571-024-00903-0

176. Anticytokine therapy and corticosteroids for cytokine release syndrome and for neurotoxicity following T-Cell engager or CAR T-cell therapy: Rapid review. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health;2024.

177. Gutierrez C, Neilan TG, Grover NS. How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy. Blood. 2023;141(20):2452-2459. doi: 10.1182/blood.2022017579

178. Ma Y, Qin J, Liu M, Du B. Allogeneic CAR-T cell therapy in autoimmune diseases. Immunotherapy. 2025;17(15):1129-1143. doi: 10.1080/1750743X.2025.2572963

179. Chen S, van den Brink MRM. Allogeneic “off-the-shelf” CAR T cells: Challenges and advances. Best Pract Res Clin Haematol. 2024;37(3):101566. doi: 10.1016/j.beha.2024.101566

180. Bot A, Scharenberg A, Friedman K, Guey L, Hofmeister R, Andorko JI, et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat Rev Drug Discov. 2026;25(2):116-137. doi: 10.1038/s41573-025-01291-5

181. Wang Q, Xiao ZX, Zheng X, Wang G, Yang L, Shi L, et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N Engl J Med. 2025;393(15):1542-1544. doi: 10.1056/NEJMc2509522